Itacitinib adipate is under clinical development by Incyte and currently in Phase II for Hairy Cell Leukemia. According to GlobalData, Phase II drugs for Hairy Cell Leukemia have a 17% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Itacitinib adipate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Itacitinib adipate overview

Itacitinib adipate (INCB-39110) is under development for the treatment of cytokine release syndrome, advanced solid tumor malignancies including sporadic hemophagocytosis lymphohistiocytosis (HLHs), advanced hepatocellular carcinoma, T-Cell Leukemia,   transitional cell carcinoma, primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (PPV-MF), post essential thrombocythemia myelofibrosis (PET-MF), B-cell lymphomas including indolent, aggressive B-cell non- Hodgkin's lymphoma, chronic lymphocytic leukemia, hairy cell leukemia, Waldenstrom macroglobulinemia, mantle cell lymphoma, diffuse large B-cell lymphoma, Hodgkin's lymphoma, myelodysplastic syndrome, myeloproliferative neoplasms, relapsed and refractory overlap syndromes, metastatic non-small cell lung cancer, acute myeloid leukemia(AML), acute lymphocytic leukemia (ALL). The drug candidate is administered orally as a tablet. INCB-39110 targets Janus kinase 1 (JAK1).
The drug candidate was also under development for  soft tissue sarcoma such as leiomyosarcoma, synovial sarcoma, pleomorphic undifferentiated sarcoma, myxoid or round cell liposarcoma, pancreatic ductal adenocarcinoma, moderate to severe ulcerative colitis, renal cell carcinoma, rheumatoid arthritis, chronic plaque psoriasis, endometrial cancer, gastric cancer, head and neck squamous cell carcinoma, melanoma, colorectal cancer, triple negative breast cancer, small cell lung cancer, urothelial cancer, ureter cancer, bladder, urethral cancer, post-lung transplant bronchiolitis obliterans syndrome (BOS) and acute graft versus host disease.

Incyte overview

Incyte is a biopharmaceutical company, that discovers, develops and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis; and polycythemia vera who are intolerant to hydroxyurea. The company distributes Jakafi through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd (Novartis) develops and commercializes ruxolitinib outside the US for hematologic and cancer indications under the name Jakavi. The company’s pipeline portfolio encompasses drugs for the treatment of lung cancer, graft versus host disease, b-cell malignancies, solid tumors, non-small cell lung cancer, glioblastoma, liver cancer, and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US.

For a complete picture of Itacitinib adipate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.